CME   /     Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers

Shownotes

Host: David H. Ilson, MD, PhD
Guest: Sunnie Kim, MD

This educational activity delves into biomarker-driven strategies for first-line therapy in metastatic gastric and gastroesophageal junction (GEJ) cancers. Participants will explore the latest clinical trial data and emerging biomarkers that guide treatment decisions. Our experts emphasize selecting optimal therapies tailored to patient-specific factors and offer strategies for managing treatment-related adverse effects. Tune in to enhance treatment efficacy and patient outcomes for your patients with metastatic gastric/GEJ cancers.